Patricia Inácio, PhD,  science writer—

Enjaymo (sutimlimab) was effective at controlling signs and symptoms of cold agglutinin disease (CAD) in a man in his 70s being given dialysis for kidney failure, a study in Japan reports. “To the best of our knowledge, this is the first report of CAD in a patient undergoing…

A third of adults with severe autoimmune hemolytic anemia (AIHA) — a group of rare conditions that includes cold agglutinin disease (CAD) — responded to intravenous immunoglobulins (IVIG), when used as an add-on therapy, after seven days, according to a retrospective study from France. The study also detailed a…

Maintaining a high temperature with the equipment used for plasmapheresis therapy in people with cold agglutinin disease (CAD), along with the environment and patients, may help prevent the risk of red blood cell clumping and destruction during the procedure, a new case report suggests. “Although our approach still…

Most children and adolescents with autoimmune hemolytic anemia (AIHA) — a group of rare conditions that includes cold agglutinin disease (CAD) — respond well to the recommended first-line treatment for adult patients, a study found. The retrospective, single-center study in Brazil found that only a minority of pediatric AIHA…

Infection with SARS-CoV-2, the virus that causes COVID-19, worsened symptoms of cold agglutinin disease (CAD) in a 71-year-old man in whom the autoimmune disease had been stable, a U.S. study reports. This case highlights the need for clinicians to be “mindful of potential preexisting … conditions, particularly [blood-related] diseases,…

A 2-year-old, healthy girl developed a severe, mixed form of autoimmune hemolytic anemia (AIHA) as a result of infection with SARS-CoV-2, the virus that causes COVID-19, a case study reports. While AIHA — a group of rare autoimmune conditions that include cold agglutinin disease (CAD) — secondary to COVID-19…

A case of cold agglutinin disease (CAD) secondary to a type of blood cancer called B-cell lymphoma was confirmed after carefully examining blood samples under the microscope, a study reports. The case study illustrates the “importance of microscopic observation in the exploration of undergoing causes of cold agglutination,” the researchers…

Enrollment for a Phase 1b basket clinical trial of povetacicept (ALPN-303), an experimental anti-inflammatory therapy, for adults with cold agglutinin disease (CAD) and other autoimmune cytopenias is expected to start in the coming months. That’s according to a corporate update from the treatment’s developer, Alpine Immune Sciences. Basket…

Enrollment is underway in a Phase 3 clinical trial testing the investigational therapy pegcetacoplan in adults with primary cold agglutinin disease (CAD), according to a corporate update from the treatment’s developer, Apellis Pharmaceuticals. The trial, called CASCADE (NCT05096403), is enrolling up to 57 patients, 18…

Signs of cold agglutinin disease (CAD) — later found to have been triggered by a previous COVID-19 infection — were detected during heart surgery in a man in Turkey, a case study showed. The case adds to several others reporting developing CAD following COVID-19 disease. Despite being rare,…